Biohaven buys GW Pharmaceuticals' PRV for $105mm; later applies it to NDA for rimegepant
Executive Summary
GW Pharmaceuticals PLC agreed to sell Biohaven Pharmaceutical Holding Co. Ltd. its rare pediatric disease priority review voucher (PRV) for $105mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Priority Review Voucher (PRV) Sale
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice